Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT02093598

NCT02093598
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with endometrial (uterine) cancer, confirmed through a tissue sample test
  • Your cancer is at an early stage (Stage I or Stage II, any grade) and surgery is planned as the main treatment
  • You are 18 years of age or older
  • You are reasonably active and able to care for yourself (your doctor will assess this using a standard scale)
  • Your blood counts, liver, and kidney are working well enough (confirmed through blood tests)
  • Your fasting cholesterol and triglyceride (fat) levels in your blood are below certain limits
  • You are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

  • You have already received any cancer treatments for your current endometrial cancer
  • You have had major surgery or a serious injury in the last 4 weeks, have not fully recovered from surgery, or may need major surgery during the study
  • You have taken part in another clinical trial involving an experimental drug in the last 4 weeks
  • You are regularly taking steroid medications or other drugs that suppress your immune system
  • You have received a live vaccine within one week before or during the study period
  • You have cancer that has spread to the brain or the lining around the brain that is not under control
  • You have had another type of cancer in the last 3 years (with some exceptions for certain skin cancers or cervical cancer that were fully treated)
  • You have other serious or uncontrolled health conditions that could affect your ability to take part
  • You have an active condition that causes uncontrolled bleeding
  • You are currently pregnant or breastfeeding, or you are of childbearing potential and not using an effective form of contraception
  • You have previously been treated with a type of drug called an mTOR inhibitor
  • You have a known allergy to rapamycin-based drugs or any of their ingredients
  • You have a history of not following medical treatment plans
  • You are unwilling or unable to follow the requirements of the study

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
MedSIR
Registry
clinicaltrials_gov
Start date
1 May 2012
Est. completion
1 March 2014

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

To evaluate the mTOR inhibitor effects of temsirolimus directly on endometrial tumor tissue after four weeks of therapy.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov